Tuberculosis Flashcards

1
Q

what is tb

A

Tuberculosis (TB) is an contagious and airborne infectious disease caused by bacteria

TB is curable and preventable

Only a small proportion of those infected will become sick with TB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what bacteria causes TB?

A

TB is caused by bacteria belonging to the Mycobacterium tuberculosis complex.

Different from Gram-positive and Gram-negative bacteria

Synthesise mycolic acids (exterior wall)

Obligate aerobes

Slow growing with incubation period about 2-10 weeks

Life cycle have different microenvironments that can affect drug susceptibility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

explain mycobacterium tuberculosis life cycle

A

1) Initial infection: a carrier exposes MTB to the air via coughing
2) Host macrophages in the lung phagocytize the pathogen Inflammatory response triggered
3) Bacterial burden is contained inside foamy macrophages
4) Macrophages form the encapsulated vascularised granuloma- Other immune cells are present

5) Granuloma matures
Cells die and caseum develops at the core of the necrotic granuloma (tubercles)
Extracellular bacilli enter their dormant state

6) Granulomas can fuse to the airways of the lungs and burst, releasing the pathogen to spread to new tissue and new hosts

A) host macrophages in the lung attempt to phagocytize the pathogen and transport it across the alveolar epithelium and into the lung. This triggers a proinflammatory response that will recruit other immune cells to form an encapsulated granuloma, which is a typical immune response to a pathogen.

B)At this point, most of the bacterial burden is contained inside what are now considered foamy macrophages which begin to line the outside of the granuloma.
C) When the granuloma is first formed, it is well vascularized and a lot of immune cells are present which bolsters the ability of drugs to reach the infection and the host’s immune system to combat the pathogen.

D) As the granuloma continues to mature against the relentless immune response, the outer wall begins to harden with a thick fibrous capsule, and the inner core is walled-off from the immune cells. Foamy macrophages line the outside of this lesion, cells die and caseum (necrotic zone, calledcaseumdue to its milky appearance) develops at the core, which cuts off the remaining vasculature. At this point, the granuloma is considered necrotic, and the bacilli exist extracellularly in this caseum and can enter their largely dormant state. Necrotic granuloma lesions (also known as tubercles) make drug penetration difficult

E)After years or in cases of immune system compromise, the granulomas will fuse to the airways of the lungs and burst, releasing the pathogen to spread to new tissue and new hosts

Each of these points in the Mtb life cycle have different microenvironments that can affect drug susceptibility. For example, various degrees of vasculature result in lower blood flow, decreased oxygen levels, and pH differences in the intra/extracellular fluids that can affect ionization or activation of drugs, drug targets in Mtb may be turned off, depending on the replication stage (latent vs. actively replicating), and the ability of the drug to penetrate tissues and membranes required to reach the mycobacteria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

who are in the risk group for TB

A

Healthcare workers or in close contacts of TB patient (especially those with sputum smear-positive disease)
People from countries with a high prevalence of TB
Immunosuppressed (e.g. high-dose steroids)
HIV positive
Immunosuppressed (e.g. high-dose steroids)
People with chronic renal failure or in haemodialysis
Haematological malignancy
Injecting drug users/Alcoholics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is the sign and symptoms of active pulmonary TB

A

Cough: >3 weeks; productive
Purulent sputum
Haemoptysis

Weight loss
Malaise
Fever
Night sweats

Symptoms of non-pulmonary TB vary depending on affected organ(s).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the clinical signs of active pulmonary TB

A
  • Sputum microscopy/culture
    Acid-fast staining of sputum smears (at least 3 samples)
  • Chest radiography
    Non specific
    Advanced TB
    White/shadowing: bronchopneumonia, lung infiltrations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
A

Primary infection
Transmission
Infection requires inhalation of particles small enough to traverse the upper respiratory defenses and deposit deep in the lung, usually in the subpleural airspaces of the middle or lower lobes. Larger droplets tend to lodge in the more proximal airways and typically do not result in infection. Infection usually begins from a single droplet nucleus, which typically carries few organisms. Perhaps only a single organism may suffice to cause infection in susceptible people, but less susceptible people may require repeated exposure to develop infection.

Pathophysiology
Natural defenses= immune system, usually control or destroy the germs once they are inhaled leaving them inactive. While one-third of the world’s population is infected withMycobacterium tuberculosis, only 5 to 10% of those infected will develop active disease.
To initiate infection,M. tuberculosisbacilli must be ingested by alveolar macrophages. Bacilli that are not killed by the macrophages actually replicate inside them, ultimately killing the host macrophage (with the help of CD8 lymphocytes); inflammatory cells are attracted to the area, causing a focal pneumonitis that coalesces into the characteristic tubercles seen histologically.
Latent TB may become active if body is weakened by other medical problems/damaged immuno system/treatment that reduce immuno defeneces (cancer treatment/ rheumatoid arthritis)

Extra-pulmonary disease
In the early weeks of infection, some infected macrophages migrate to regional lymph nodes (eg, hilar, mediastinal), where they access the bloodstream. Organisms may then spread hematogenously to any part of the body, particularly the apical-posterior portion of the lungs, epiphyses of the long bones, kidneys, vertebral bodies, and meninges. Hematogenous dissemination is less likely in patients with partial immunity due to vaccination or to prior natural infection withM. tuberculosisor environmental mycobacteria.

Extra-pulmonary disease
Infected macrophages access the bloodstream.
Infection is not primarily located in the lungs but in other organs e.g., lymph nodes, pleura, abdomen, genitourinary tract, skin, joints and bones, or meninges
More common in children <4 yr, patients with immunosuppression or HIV and the elderly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the first line management of tb

A

Initial phase, 2 months treatment with:

Isoniazid (H)
Rifampicin (R)
Pyrazinamide (Z)
Ethambutol (E)

Continuation phase, further 4 months treatment with:
Rifampicin
Isoniazid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the mechanism of action of isonazid
effects
pharmokenetics
adverse effects

A
  • Inhibition of Biosynthesis of mycolic acids
  • Synthesis of cell wall

Mechanism of action:
Inhibits biosynthesis of mycolic acids constituents of mycobacterial cell wall
Prodrug: activated by bacterial catalase

Effects:
Bacteriostatic for resting bacilli
Bactericidal for extracellular dividing microorganisms

Pharmacokinetic
Orally active
Metabolism: by acetylation
Slower acetylators respond well!!

Adverse effects: 5% of patients
Peripheral neuropathy
Autoimmune phenomena and blood disorders: agranulocytosis, anaemia
Hepatotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the mechanism of action of Ethambutol

A

Inhibition of Arabinoyl Transferase
Synthesis of cell wall

Uncertain
Impairs biosynthesis of bacterial cell wall
Orally active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the mechanism of action of Rifampicin

A

Inhibition of RNA polymerase

Inhibits DNA-dependent RNA polymerase of mycobacteria
Orally active

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the mechanism of action of Pyrazinamide

A

Intracellular acidification
Plasma Membrane disruption

Uncertain
M ay involve metabolism of drug within bacteria to produce toxic product
Pro-drug converted to its active form (pyrazinoic acid) by pyrazinamidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the effects of Rifampicin

A

Bactericidal effect on the three MTB population

MTB populations and environments

1) Open pulmonary cavities: plenty of oxygen, rapid growth, drug resistance develops!
2) Closed lesions in the lung: oxygen starved, slow growing/dormant bacilli, poor blood supply, limited penetration of drug
3) Intracellular: low pH, drugs may be inactive, lack of oxygen, slow/ intermittent growing bacilli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the side effects of rifampicin
adverse effect
drug interactions

A

Side effects:
Causes orange-red coloration of urine and other body fluids (important for soft contact lenses users!)

Adverse effect: rare BUT serious:
Hepatotoxicity
Toxic syndrome

Drug interactions: many!
It induces hepatic metabolising enzymes increasing degradation of warfarin, glucocorticoids, analgesic, oestrogen!
NOTE: in patient using oral contraceptives, alternative family planning advice should be offered

Rapid development of resistance!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the effects/ adverse effects and pharmokenetics of ethambutol

A

Pharmacokinetic
Orally active

Effects: bacteriostatic (selective for mycobacteria)

Adverse effects:
Uncommon
Optic neuritis: changes in colour vision or visual field – usually reversible (check visual acuity before treatment and repeat regularly)
In children use it with care! Why?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

why do you need to take care when giving ethambutol to children?

A

becauseofconcern abouttheriskof ocular toxicityandthe difficultyof assessingocular functioninyoungchildren

17
Q

what is the effects/ adverse effects and pharmokenetics of Pyrazinamide

A

Effects:
Bacteriostatic at acidic pH
Interferes with the bacterium’s ability to synthesize new fatty acids, required for growth and replication.

Pharmacokinetic
Orally active and widely distributed

Adverse effects:
Hepatotoxicity
Increased plasma urate (gout!)

Resistance can develop rapidly!

18
Q

what happens when Pyrazinamide diffuses intoM. tuberculosis

A

Pyrazinamide diffuses intoM. tuberculosis, where the enzyme pyrazinamidase converts pyrazinamide to the active form pyrazinoic acid. Under acidic conditions, the pyrazinoic acid that slowly leaks out converts to the protonated conjugate acid, which is thought to diffuse easily back into the bacilli and accumulate.

19
Q

Children MAY NOT be able to use combination treatment! Why?

A

Although not licensed in children, consideration may be given to use ofRifaterin older children, provided the respective dose of each drug is appropriate for the weight of the childRifinah Not licensed for use in children.

Rifater® – combination of rifampicin: isoniazid : pyrazinamide (120 mg: 50 mg: 300 mg)

Rifinah® – combination of rifampicin : isoniazid (Rifinah 150=150 mg :100 mg; Rifinah300 =300 mg :150 mg)

20
Q

what is latent TB?

A

Latent TB is where you’ve been infected with the TB bacteria, but do not have any symptoms of active infection.

21
Q

what are the methods for diagnosis of Latent TB?

A

Mantoux test: tuberculinskintest. Read 48-72 hours later.

tuberculin PPD (purified protein derivative) extracted from TB cultures is injected into the top layers of skin of the forearm.

Induration diameter:
0-5 mm: Negative
6-14 mm: Positive: infection with Mycobacterium tuberculosis, infection with nontuberculous mycobacteria, previous Bacillus Calmette-Guérin (BCG) vaccination
>15 mm: Strongly positive: TB infection/disease

22
Q

how can you manage latent TB?

A

3 months of isoniazid AND rifampicin OR
6 months of isoniazid (New 2016)
Both with pyridoxine-Vitamin B6

Caution if liver function and hepatotoxicity are of concern!

23
Q

which individuals will receive treatment for latent TB?

A
Treatment offered to individuals with latent TB at increased risk of developing active TB
HIV-positive
<5 years old
Alcohol /injecting drug (ab)users 
Immunosuppress
Chronic illness
24
Q

what is extra- pulmonary TB?

A

Active TB disease in any site other than the lungs or tracheobronchial tree.

25
Q

How can you diagnose extra - pulmonary TB?

methods

A

Imaging technique, biopsy and needle aspiration

Site-specific investigations
Central nervous system e.g., Cerebrospinal fluid microscopy culture
Lymph node e.g., Ultrasound and Biopsy
Pericardial e.g., Echocardiogram and Biopsy

26
Q

what is the treatment for extra-pulmonary TB?

A

Treatment: similar to pulmonary TB

Longer antibiotic treatment and use of corticosteroids (i.v. and then oral) in CNS TB

27
Q

Drug resistant TB?

Which 2 drugs?

A

Drug-Resistant TB in UK
Isoniazid (6%, 2008)
Rifampicin (1.5%, 2008)

28
Q

how can you manage drug resistant TB?

A

Management:

Combine remaining available 3 drugs
Extend duration of continuation treatment up to 10 month.

29
Q

what is Multidrug-Resistant TB?

and management

A

resistant to isoniazid and rifampicin, with or without any other resistance

Multi disciplinary team, TB specialist
Individualized treatment
Complex regimen
Multiple reserve drugs
High costs! 50-70 K / treatment!!
30
Q

why are resistance developed?

A

Inadequate dosing

Incomplete treatment regimens

This intrinsic resistance is partially due to the thick, lipid-rich cell wall, which is an important characteristic of mycobacteria, limiting the penetration of antibiotics.

Moreover, mycobacteria possess various defence systems against the activity of antibiotics, including potent β-lactamases and other drug-neutralizing enzymes

Drug resistance arises through the acquisition of specific chromosomal mutations: Drug resistance-conferring mutations inM. tuberculosis have been described in genes encoding enzymes directly targeted by the antibiotics, in regulatory regions of these genes, or in gene products involved in the activation of pro-drugs

31
Q

what are the second line of treatment for TB?

A

(aminoglycosides) Streptomycin
(aminoglycosides) Amikacin
(aminoglycosides) Capreomycin
(fluoroquinolones) Ofloxacin
(fluoroquinolones) Ciprofloxacin
(macrolides) Azithromycin
(macrolides) Clarithromycin
Cycloserine
P-aminosalicylate
Moxifloxacin
Bedaquiline
Delamanid (new from 2014 )

32
Q

what are some counselling points for patient care for tb?

A

PIL
Rifampicin and body fluid discolouration
Rifampicin and use of oral contraceptive
Ocular side effects of ethambutanol

33
Q

Infectious disease
Pulmonary and Extra-pulmonary
Active and Latent

Signs and symptoms
Cough >3 weeks ; productive; purulent sputum
Haemoptysis, weight loss, malaise, fever, night sweats

Treatments with antimycobacterials
Active pulmonary: 2+4 months
Extra-pulmonary: (prolonged) 2+10 months
LTBI: (preventive) 3 or 6 months

Prevention: vaccination available

A
34
Q

what are the vaccinations given for TB?

A

BCG (Bacille Calmette-Guérin) vaccination
Contains live, weakened M. Bovis.
Gives 60-80% protection against TB infection in childhood but loses efficacy in adulthood – variable across the globe.
Immunization in UK is now a risk-based programme

Discussed e.g., Neonatal BCG vaccination for any baby at increased risk of TB

Offered e.g., New entrants from high-incidence areas; healthcare workers, other groups of people e.g., veterinary, prison staff working directly with prisoners, staff of care homes for elderly people, of hostels for homeless people, people going to live or work in a high-incidence country

35
Q

what are all the Diagnosis of TB?

A

T-cell interferon-gamma release assay - overnight incubation
mantoux test